No Data
No Data
Guggenheim Reiterates Buy on Prime Medicine, Maintains $18 Price Target
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Maintains Target Price $5
Prime Medicine, Inc. (PRME) Gets a Hold From Morgan Stanley
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $7 to $14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?